190 related articles for article (PubMed ID: 3106101)
1. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization.
Neveu S; Hedon B; Bringer J; Chinchole JM; Arnal F; Humeau C; Cristol P; Viala JL
Fertil Steril; 1987 Apr; 47(4):639-43. PubMed ID: 3106101
[TBL] [Abstract][Full Text] [Related]
2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
3. Controlled ovarian hyperstimulation for in vitro fertilization using buserelin and gonadotropin in patients with previous failed cycles.
Loong EP; Tam PP; Chiu TT; Chan MY; Panesar NS; Lau J
Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):297-300. PubMed ID: 2129187
[TBL] [Abstract][Full Text] [Related]
4. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
[TBL] [Abstract][Full Text] [Related]
5. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist.
Itskovitz J; Boldes R; Levron J; Erlik Y; Kahana L; Brandes JM
Fertil Steril; 1991 Aug; 56(2):213-20. PubMed ID: 1906406
[TBL] [Abstract][Full Text] [Related]
6. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
Lanzone A; Fulghesu AM; Spina MA; Apa R; Menini E; Caruso A; Mancuso S
J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
[TBL] [Abstract][Full Text] [Related]
7. The effects of gonadotrophin-releasing hormone agonist on follicular development in patients with polycystic ovary syndrome in an in-vitro fertilization and embryo transfer programme.
Gersak K; Meden-Vrtovec H; Tomazevic T
Hum Reprod; 1994 Sep; 9(9):1596-9. PubMed ID: 7836506
[TBL] [Abstract][Full Text] [Related]
8. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
9. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study.
Howles CM; Loumaye E; Giroud D; Luyet G
Hum Reprod; 1994 Mar; 9(3):424-30. PubMed ID: 8006130
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of different ovarian stimulation protocols for in vitro fertilization.
Pados G; Tarlatzis BC; Bontis J; Lagos S; Papadimas J; Spanos E; Mantalenakis S
Gynecol Endocrinol; 1995 Jun; 9(2):103-12. PubMed ID: 7502685
[TBL] [Abstract][Full Text] [Related]
11. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization.
MacLachlan V; Besanko M; O'Shea F; Wade H; Wood C; Trounson A; Healy DL
N Engl J Med; 1989 May; 320(19):1233-7. PubMed ID: 2496310
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy following induction of ovulation with pure FSH after suppression of endogenous gonadotropins with subcutaneous buserelin.
Albert PJ; Schläfke J; Kaesemann H; Gille J
Arch Gynecol Obstet; 1987; 241(1):53-6. PubMed ID: 3118825
[TBL] [Abstract][Full Text] [Related]
13. In vitro fertilization for women with pure tubal occlusion: the impact of short gonadotropin-releasing hormone agonist treatment.
Luxman D; Cohen JR; Lessing JB; Yovel I; David MP; Ami A
Fertil Steril; 1995 Feb; 63(2):357-60. PubMed ID: 7843443
[TBL] [Abstract][Full Text] [Related]
14. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
15. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
16. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
Gerris J; De Vits A; Joostens M; Van Royen E
Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
[TBL] [Abstract][Full Text] [Related]
18. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
19. [Stimulation of ovarian function with gonadotropins following suppression of endogenous gonadotropin secretion by long-term infusion of the LHRH analog buserelin].
Geisthövel F; Bliefert R; Geyer H; Breckwoldt M; Sandow J
Geburtshilfe Frauenheilkd; 1987 Apr; 47(4):240-5. PubMed ID: 3109997
[TBL] [Abstract][Full Text] [Related]
20. Pituitary and ovarian suppression rate after high dosage of gonadotropin-releasing hormone agonist.
Bider D; Ben-Rafael Z; Shalev J; Goldenberg M; Mashiach S; Blankstein J
Fertil Steril; 1989 Apr; 51(4):578-81. PubMed ID: 2494078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
